Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower price

NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to

Novo Nordisk was first with a GLP-1 weight-loss shot, but lost the lead to Eli Lilly. Novo Nordisk w

Novo Nordisk shares fell on Thursday after Deutsche Bank downgraded the Danish drugmaker to Sell fro

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker's ability to return to growt

The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying

Novo Nordisk (NYSE:NVO) has received a downgrade from Deutsche Bank, with analysts lowering their ta

While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been rel

China's ​drug ‌regulator has accepted ​Novo ​Nordisk's marketing ⁠application ​for the ​oral version

Boston Scientific reports a cyber incident disrupting global operations, limiting system access and

Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a glo

For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lowe

Duquesne Family Office has beefed up its healthcare holdings.

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO) both reported Q2 2026 result

PERTH, Western Australia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Compan

Eli Lilly's weight-loss and diabetes pill goes on sale in UK pharmacies from Monday, giving patients

Eli Lilly's weight-loss and diabetes pill goes on sale in UK pharmacies from Monday, giving patients

Novo Nordisk stock appears to have formed a long-term bottom, with its turnaround gaining traction a

On August 24, 2026, we delve into the DCF analysis for Novo Nordisk AS (NVO), a company currently fa

Novo Nordisk A/S maintains a Buy rating, driven by strong Wegovy pill uptake and a robust GLP-1 fran

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the c

Celon Pharma's experimental semaglutide product Reduzek, a generic alternative to Novo ​Nordisk's We

Novo Nordisk A/S remains a Strong Buy, trading at just 12.5x P/E despite robust growth and global ex

Hims & Hers CEO Andrew Dudum defends the firm against an FTC lawsuit, discusses dropping GLP-1 d

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $4

Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducin

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping th

Amazon Pharmacy offers eligible Medicare patients weight-loss drugs for $50 monthly under a new fede

A Dutch court has banned sales of an unapproved compounded semaglutide nasal spray following a legal

Bank of America spends over $250 million yearly on GLP-1 drugs, with CEO Brian Moynihan calling it a

CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options.New colla

Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.96 per share which beat the analyst consen

Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls

Novo Nordisk today announced adjusted sales and adjusted operating profit for the second quarter of

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

SanDisk, Western Digital and eight other names carry the biggest implied earnings moves in the first

BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concer

Novo Nordisk Phase 3 ZEUS trial shows ziltivekimab missed MACE risk reduction. Operating profit outl

Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial.Wh

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), t

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketi

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Li